<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788943</url>
  </required_header>
  <id_info>
    <org_study_id>nAChR-PET-quit</org_study_id>
    <nct_id>NCT01788943</nct_id>
  </id_info>
  <brief_title>Nicotine Receptor Levels and Smoking Cessation</brief_title>
  <official_title>Nicotinic Receptor Availability and Smoking Cessation Success.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to use positron emission tomography (PET) imaging to determine
      whether nicotinic receptor availability at pretreatment predicts smoking cessation success.
      The investigators will recruit 30 smokers from those enrolled in the Pharmacogenetics of
      Nicotine Addiction Treatment clinical trial. The investigators will measure nicotinic
      receptor availability using the PET radioligand 2-[18F]FA, after overnight abstinence and
      prior to initiation of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be asked to complete a short screening session, an orientation phone call, and
      two imaging sessions: one PET imaging session and one MRI session.

      Intake Session. This session will familiarize subjects with the study procedures and risks,
      as well as determine initial eligibility for the study. Subjects will first complete an
      Imaging Screening Form with study personnel. Subjects will also complete a Magnet Safety Form
      to check for any metal in the body. Finally, subjects will complete a Scanning Registration
      Form.

      Orientation Call. Dr. Dubroff (the Principal Investigator and study physician) will call
      subjects before the PET Scan Session to review the study procedures and risks and answer any
      questions subjects might have.

      PET Scan Session. Subjects will receive a telephone call the day before the session to remind
      them to stop smoking at 9:00pm that night. At the session, they will provide a series of
      samples. These include:

        -  A urine sample to assess for the presence of study-prohibited drugs and medications
           (including cocaine, opiates, benzodiazepines, amphetamines, methamphetamines, tri-cyclic
           antidepressants, methadone, PCP, and barbiturates).

        -  Women of childbearing age will be required to take a urine pregnancy test.

        -  A breath alcohol concentration (BrAC) measurement.

        -  A breath carbon monoxide (CO) reading.

        -  Have your weight measured.

      After subjects arrive at the PET center, they will have two intravenous (I.V.) lines placed.
      A sterile solution will be dripped through the tubing to keep them open. Subjects will have
      blood pressure and heart rate taken prior to injection and three 10ml tubes of blood will be
      drawn to determine the baseline levels of radioactive tracer. After this, subjects will be
      injected with a radioactive tracer (a chemical that has a radioactive molecule attached to
      it) called 2-[18F]FA that will be pumped through one of the I.V. lines over an 8-hour period.
      During the waiting period subjects will complete two questionnaires, a brief IQ test, and
      five computer games. They will have repeated blood pressure and heart rate readings taken
      soon after the initial injection and every 45 minutes afterwards. The investigators will draw
      3 ml (half a teaspoon) of blood from the second I.V. line every 15-30 minutes to measure
      radiotracer levels.

      Just prior to beginning the scan, subjects will be asked two questions about cravings. These
      questions will be asked every 30 minutes during the scan and then once more after subjects
      have exited the scan. The investigators will draw one 3ml tube of blood at the beginning of
      the PET scan and every 30 min during the PET scan (total 5 teaspoons) from the second I.V.
      line to measure radiotracer levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acetylcholinergic Nicotine Receptor Availability as Determined by 2FA -PET Brain Imaging.</measure>
    <time_frame>following overnight nicotine abstinence</time_frame>
    <description>Acetylcholinergic Nicotine Receptor availability in the thalamus is decreased in smokers with slower rates of nicotine metabolism.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cigarette Craving as Measured by the Questionnaire on Smoking Urges.</measure>
    <time_frame>Before and immediately following the PET scan.</time_frame>
    <description>Measure is post-scan subtracted from pre-scan ratings. Rating is measured using the standardized, Questionnaire on Smoking Urges - Brief Version (QSU-Brief) is a standardized measure consisting of 10 statements, each rated on a Likert-like scale from 1 (Strongly Disagree) to 7 (Strongly Agree). Responses for each item are summed to produce an overall score with a range of 10-70.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Nicotine Addiction</condition>
  <arm_group>
    <arm_group_label>Slow metabolizers</arm_group_label>
    <description>Individuals with an NMR &lt;0.26 will be classified as slow metabolizers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal metabolizers</arm_group_label>
    <description>Participants with an NMR &gt;= 0.26 will be classified as normal metabolizers.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion Criteria:

        Participants will be male and female smokers between the ages of 18 and 65 and must be
        enrolled(consented and meet all eligibility requirements) in the ongoing PNAT trial
        [NCT01314001] in order to participate in this sub-study. They must be able to provide
        informed consent and weigh less than 300 lbs (due to limitations of the PET and MRI
        scanners).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Exclusion Criteria:

        In addition to the exclusion criteria used for PNAT trial [NCT01314001], participants in
        this trial will be excluded if they meet the following criteria:

        Imaging-Related Exclusion Criteria:

          1. Weigh over 299 lbs.

          2. Self-reported history of head trauma or brain (or CNS) tumor.

          3. Self-reported history of claustrophobia (contraindicated for PET and MRI).

          4. Cochlear implant or bilateral hearing aids.

          5. Pacemakers, certain metallic implants, or presence of metal in the eye as
             contraindicated for MRI.

          6. History of gunshot wound (including BB guns).

          7. Circumstances or conditions that may interfere with magnetic resonance imaging (MRI).

          8. CO reading greater than 15ppm at the PET Scan Session (or at least a 50% reduction
             from the PNAT Intake Session).

          9. BrAC reading greater than or equal to 0.01 at the PET Scan Session.

         10. Positive urine drug screen for cocaine, phencyclidine, amphetamines, methamphetamines,
             tricyclic antidepressants, opiates, methadone, benzodiazepines, or barbiturates at the
             PNAT Intake Session or PET Scan Session.

         11. Positive urine pregnancy (females only) screen at the PET Scan Session and/or MRI Scan
             Session.

         12. Inability to give blood at the PET Scan Session (blood samples are required to analyze
             PET data).

         13. Prior exposure to radioactive tracers in imaging studies or for medical reasons may be
             exclusionary.

        General Exclusion Criteria:

          1. Any medical condition, illness, disorder or concomitant medication that could
             compromise participant safety or treatment, as determined by the Principal
             Investigator or Co-investigators.

          2. Inability to provide informed consent or complete the study procedures within 10 hours
             and/or correctly, as determined by the Principal Investigator or Co-investigators.

          3. Any physical or visual impairment that would prevent completion of the cognitive
             tasks.

          4. Participation (within the last 6 months) in other studies at our center involving
             similar cognitive testing procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.upenn.edu/apps/faculty/index.php/g334/p6489091</url>
    <description>Principal Investigator</description>
  </link>
  <link>
    <url>http://www.med.upenn.edu/cirna/</url>
    <description>Center for Interdisplinary Research on Nicotine Addiction</description>
  </link>
  <link>
    <url>http://www.uphs.upenn.edu/radiology/research/labs/pet-positron-emission-tomography/</url>
    <description>Position Emission Tomography (PET) Center at the University of Pennsylvania</description>
  </link>
  <reference>
    <citation>Brody AL, Mandelkern MA, London ED, Olmstead RE, Farahi J, Scheibal D, Jou J, Allen V, Tiongson E, Chefer SI, Koren AO, Mukhin AG. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006 Aug;63(8):907-15.</citation>
    <PMID>16894067</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>August 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2018</results_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Jacob Dubroff</investigator_full_name>
    <investigator_title>Assistant Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>positron emission tomography</keyword>
  <keyword>nicotine receptor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>10/01/2012-03/28/2014 recruitment at the Center for Interdisciplinary Research on Nicotine Addiction at the University of Pennsylvania</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Slow Metabolizers.</title>
          <description>Participants with an NMR &lt; 0.26 will be considered slow metabolizers.</description>
        </group>
        <group group_id="P2">
          <title>Normal Metabolizers</title>
          <description>Participants with an NMR &gt;= 0.26 will be considered normal metabolizers.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">Recruitment for study began.</participants>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">2FA-PET Brain Image Analysis Completion Date</participants>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Nicotine Metabolizers</title>
          <description>Nicotine Metabolite Radio of &gt; or = 0.26</description>
        </group>
        <group group_id="B2">
          <title>Slow Nicotine Metabolizers</title>
          <description>Nicotine Metabolite Radio of &lt; 0.26.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" lower_limit="35" upper_limit="64"/>
                    <measurement group_id="B2" value="45.5" lower_limit="23" upper_limit="62"/>
                    <measurement group_id="B3" value="47.1" lower_limit="23" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acetylcholinergic Nicotine Receptor Availability as Determined by 2FA -PET Brain Imaging.</title>
        <description>Acetylcholinergic Nicotine Receptor availability in the thalamus is decreased in smokers with slower rates of nicotine metabolism.</description>
        <time_frame>following overnight nicotine abstinence</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Slow Metabolizers.</title>
            <description>Subjects with an NMR &lt; 0.26.</description>
          </group>
          <group group_id="O2">
            <title>Normal Metabolizers</title>
            <description>Subjects with an NMR of &gt; or = 0.26.</description>
          </group>
        </group_list>
        <measure>
          <title>Acetylcholinergic Nicotine Receptor Availability as Determined by 2FA -PET Brain Imaging.</title>
          <description>Acetylcholinergic Nicotine Receptor availability in the thalamus is decreased in smokers with slower rates of nicotine metabolism.</description>
          <units>Distribution Volume Ratio (Vt/fp)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="2.4"/>
                    <measurement group_id="O2" value="26.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cigarette Craving as Measured by the Questionnaire on Smoking Urges.</title>
        <description>Measure is post-scan subtracted from pre-scan ratings. Rating is measured using the standardized, Questionnaire on Smoking Urges - Brief Version (QSU-Brief) is a standardized measure consisting of 10 statements, each rated on a Likert-like scale from 1 (Strongly Disagree) to 7 (Strongly Agree). Responses for each item are summed to produce an overall score with a range of 10-70.</description>
        <time_frame>Before and immediately following the PET scan.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Slow Metabolizers.</title>
            <description>Subjects with an NMR &lt; 0.26.</description>
          </group>
          <group group_id="O2">
            <title>Normal Metabolizers</title>
            <description>Subjects with an NMR of &gt; or = 0.26.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cigarette Craving as Measured by the Questionnaire on Smoking Urges.</title>
          <description>Measure is post-scan subtracted from pre-scan ratings. Rating is measured using the standardized, Questionnaire on Smoking Urges - Brief Version (QSU-Brief) is a standardized measure consisting of 10 statements, each rated on a Likert-like scale from 1 (Strongly Disagree) to 7 (Strongly Agree). Responses for each item are summed to produce an overall score with a range of 10-70.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="10.1"/>
                    <measurement group_id="O2" value="1.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will examine the day of and the day following PET scanning.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Slow Metabolizers (NMR &lt; 0.26)</title>
          <description>No serious adverse events were observed.</description>
        </group>
        <group group_id="E2">
          <title>Normal Metabolizers (NMR &gt; or + 0.26)</title>
          <description>No serious adverse events were observed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jacob Dubroff,M.D., Ph.D., Assistant Professor of Radiology</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-662-3041</phone>
      <email>jacob.dubroff@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

